Journal article
Omeprazole: a new approach to gastric acid suppression
American family physician, v 41(4), pp 1225-1227
Apr 1990
PMID: 2321497
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Omeprazole, one of a new group of antisecretory drugs, is a substituted benzimidazole that does not exhibit the anticholinergic or histamine H2 antagonistic properties of drugs such as cimetidine. This agent suppresses gastric acid secretion by inhibiting the proton pump mechanism, thereby blocking the final step of acid secretion. Omeprazole is significantly more effective than the histamine H2 receptor antagonists in eliminating acid secretion; thus, it may be beneficial in patients who are resistant to these agents. Omeprazole is indicated for severe erosive esophagitis, gastroesophageal reflux disease that does not respond to H2 receptor antagonists, and hypersecretory diseases such as Zollinger-Ellison syndrome and systemic mastocytosis. Because of the theoretic risk of carcinogenesis, short-term therapy is recommended, although long-term therapy is required for hypersecretory diseases.
Metrics
6 Record Views
Details
- Title
- Omeprazole: a new approach to gastric acid suppression
- Creators
- K Buhl - Division of Gastroenterology, Hahnemann University School of Medicine, Philadelphia, PennsylvaniaH R Clearfield
- Publication Details
- American family physician, v 41(4), pp 1225-1227
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- [Retired Faculty]
- Web of Science ID
- WOS:A1990CX51700022
- Scopus ID
- 2-s2.0-0025308535
- Other Identifier
- 991019184198004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Primary Health Care